DP1 Declares 25% Cash Dividend for 2025, Record Date Sept 9
This Aveluro analysis covers DP1 on UPCOM in the Health Care sector. The classified event type is dividend announcement, with positive sentiment and a deterministic market-impact score of 5.6/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Dược phẩm Trung ương CPC1 (DP1) has announced a 25% cash dividend for fiscal year 2025, with a record date of September 9 and payment scheduled for October 15, 2026. The company, listed on UPCOM, will distribute over VND 52 billion to shareholders. This follows a strong second quarter where net profit doubled year-on-year.
Key Facts
- Dividend rate: 25% cash, equivalent to VND 2,500 per share.
- Record date: September 9, 2026; payment date: October 15, 2026.
- Total payout: over VND 52 billion based on 20.8 million outstanding shares.
- Dividend plan approved at the Annual General Meeting on April 21.
- Q2 2026 net revenue: nearly VND 677 billion, up 24% year-on-year.
- Q2 2026 net profit: VND 44 billion, double the VND 22 billion in Q2 2025.
- H1 2026 net revenue: VND 1,246 billion (+21%); net profit: VND 66 billion (+24%).
- DP1 closed at VND 30,900 on August 24, 2026, with market capitalization near VND 650 billion.
What Happened
CPC1 announced that it will finalize the shareholder list on September 9 to execute the 2025 cash dividend payment. Shareholders will receive VND 2,500 per share, representing a 25% yield on par value. The company expects to disburse more than VND 52 billion, with payment slated for October 15, 2026. The dividend plan was approved at the annual general meeting held on April 21.
In a related corporate governance move, CPC1 accepted the resignation of General Director Tạ Văn Dũng, effective July 31, 2026. The company’s operational performance remains robust: Q2 2026 net revenue rose 24% to nearly VND 677 billion, and net profit doubled to VND 44 billion. For the first half of 2026, revenue reached VND 1,246 billion (+21%) and net profit VND 66 billion (+24%).
Market Context
DP1 trades on UPCOM and closed at VND 30,900 on August 24, 2026, with a market capitalization of approximately VND 650 billion. The stock’s price implies a dividend yield of about 8.1% based on the announced cash dividend, which is attractive relative to typical yields on the Vietnamese market. The company’s pharmaceutical sector has shown resilience, and the doubling of Q2 net profit underscores operational momentum.
Strategic Significance
The 25% cash dividend signals strong cash flow generation and a shareholder-friendly policy, which may appeal to income-focused investors. The doubling of net profit in Q2 suggests improving operational efficiency and market demand. However, the recent change in general management introduces leadership transition risk. Long-term investors should monitor whether the new management sustains growth and maintains dividend consistency.
What to Watch
- Q3 2026 earnings release to confirm sustained profit growth.
- Appointment of a new General Director and any strategic shifts.
- Dividend payment execution on October 15, 2026.
- Any regulatory changes affecting the pharmaceutical sector.
- DP1’s price movement around the record date, which may see increased trading activity.